NICE Accredits Endomag’s Magtrace® Lymphatic Tracer for Staging Breast Cancer
Retrieved on:
Wednesday, August 18, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Sentinel, NHS England, Union, Lymphatic system, Biopsy, Five Year Forward View, Government, University, National Institute for Health and Care Excellence, Cancer, Endomag, Lymph node, Kate Williams, Neoplasm, Science, Physician, European Union, Systematic review, Research, Accreditation, NICE, UCL, Lymph, Heart, Sentinel lymph node, Allergy, Hospital, Health, Multimedia, England, Methylene blue, Magnetism, Meta-analysis, NHS, Risk, Radionuclide, PLOS One, Patient, CEO, North Manchester, North Manchester General Hospital, Breast cancer, Woman, National Institute, Technology, University College London, Medical imaging, Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology
Endomags lymphatic tracer, Magtrace, has received an accreditation from the National Institute for Health and Care Excellence (NICE) for locating sentinel lymph nodes.
Key Points:
- Endomags lymphatic tracer, Magtrace, has received an accreditation from the National Institute for Health and Care Excellence (NICE) for locating sentinel lymph nodes.
- To determine if breast cancer has spread, doctors analyse the sentinel, or nearest, lymph nodes to the tumour to see if they contain cancer cells.
- Unlike technetium-99m, the Magtrace lymphatic tracer is manufactured in the UK and requires no nuclear facilities to be stored or used.
- Endomag welcomes NICEs accreditation of the Magtrace lymphatic tracer and will continue to work to support access and improve standards of care for all breast cancer patients.